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Abstract Measles is one of the 
most infectious diseases known to 
affect man. It spreads rapidly from 
an index case to many susceptible 
individuals resulting in cycles of 
epidemics in different parts of the 
world especially in the African con-
tinent. The contribution of measles 
to childhood mortality and morbid-
ity remains high because it gives 
rise to complications such as pneu-
monia, malnutrition and blindness. 
Measles vaccine is known to be 
efficacious and effective; however 
appearance of epidemics in parts of 
Europe and the USA in recent times 
underscores the fact that low vac-
cine uptake will always leave a 
large number of susceptible indi-
viduals with a potential for epidem-
ics. The history, aetiopathogenesis, 
clinical features (including compli-
cations), diagnostic tools, treatment 
and prevention are discussed in this 
article. The most important steps to 
prevent measles cases and deaths 
would be to institutionalize the two 
dose measles vaccine regime; give 
supplemental Vitamin A; strengthen 
health systems to be able to ade-
quately deliver the vaccine and sup-
plement, carry out surveillance and 
offer treatment for cases. There is 
no doubt that global partnerships 
remain relevant in order to consoli-
date and accelerate prevention of 
measles, thus, they must continue to 
be supported. 
Introduction 
Reports of measles go back to at least 700BC. However, 
the first scientific description of the disease and its dis-
tinction from smallpox attributed to the Muslim physi-
cian Ibn Razi(Rhazes) 860-932 who published a book 
entitled "Smallpox and Measles" (in Arabic: Kitab fi al-
jadari wa-al-hasbah).  
 
The Facts  
 
Measles remains a leading cause of death among young 
children globally, despite the availability of a safe and 
effective vaccine. An estimated 197 000 people died 
from measles in 2007, mostly children under the age of 
five. In developing countries, measles affects 30 million 
children a year and causes 1 million deaths. Measles 
causes 15,000-60,000 cases of blindness per year.  Ap-
proximately 30 million measles cases are reported annu-
ally. Most reported cases are from Africa. In 1998, the 
cases of measles per 100,000 total population report d 
to the World Health Organization was 1.6 in the Ameri-
cas, 8.2 in Europe, 11.1 in the Eastern Mediterranean 
region, 4.2 in South East Asia, 5.0 in the Western Pa-
cific region, and 61.7 in Africa. Only 187 confirmed 
cases were reported in the Western Hemisphere  
(mainly in Venezuela, Mexico, and the United States) 
(Fig 1– 5) 
 
Fig 1 
Fig 2 : Nigerian incidence series over 10 years (Source: WHO)  
Fig 3 : A 5-year measles admission in EPU, UITH  
Fig 4: EPU admission in the last 5 months (as at 7th March, 
2011) 
 
Fig 5: Deaths from Measles admitted in EPU over 5 years  
 
Measles   
 
It is an infection of the respiratory system caused by a 
virus, specifically Paramyxoviruses of the genus Morbil-
livirus Morbilliviruses, like other paramyxoviruses, are 
enveloped, single-stranded, negative-sense RNA vi-
ruses.  The measles virus is a spherical,   non segmented, 
single-stranded RNA virus in the Morbillivirus family, 
closely related to the rinderpest and canine distemper 
viruses.  It contains six structural proteins, three that are 
complexed to the RNA and three that are associated with 
the viral membrane envelope. The F (fusion) protein is 
responsible for fusion of virus and host cell membranes, 
viral penetration and hemolysis.  The H (hemagglutinin) 
protein is responsible for adsorption of the virus to 
cells.  There is only one serotype of Measles virus and 




The essential lesion of measles is found in the skin, con-
junctivae, and mucous membranes of nasopharynx, 
bronchi, and intestinal tract. Serous exudate and prolif-
eration of mononuclear cells and a few polymorphonu-
clear cells occur around the capillaries. Hyperplasia of 
lymphoid tissue usually occurs particularly in the appen-
dix.  The pathologic lesion is the Warthin-Finkeldey 
giant cell. These are multinucleated reticuloendothelial 
giant cells of up to 100 micrometers in diameter. 
In the skin, this reaction can be noted around the seba-
ceous glands and hair follicles. Koplik spots consist of 
serous exudate and proliferation of endothelial cells 




Measles is spread through respiration (contact withflu-
ids from an infected person's nose and mouth, either 
directly or through aerosol transmission), and is highly 
contagious—90% of people without immunity sharing a 
house with an infected person will catch it. The inf ction 
has an average incubation period of 14 days (range 6-19 
days).  Infectivity lasts from 2-4 days prior to 2-5 days 
following the onset of the rash. Replication occurs in 
nasopharynx and regional lymph nodes. Primary virae-
mia occurs 2-3 days after exposure while secondary 





Incubation period ranges from 6-19 days. It has a pro-
dromal period which presents with stepwise increase in 
fever to 39.40C or higher, cough, coryza, conjunctivitis 
and Koplik spots (rash on mucous membranes). 
 
The rash occurs 2-4 days after prodrome and 14 days
after exposure. It is maculopapular and later become 
confluent beginning on face and head. It persists 5-6 
days and fades in order of appearance. Patients are con-
tagious from 1-2 days before onset of symp-
toms. Healthy children are also contagious during the 
period from 3-5 days before the appearance of the rash
to 4 days after the onset of rash. On the other hand, im-
munocompromised individuals can be contagious during 
the entire duration of the illness.  
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Risk factors for infection  
 
Risk of infection is increased among children with im-
munodeficiency due to HIV or acquired immunodefi-
ciency syndrome (AIDS), leukemia, alkylating agents, 
or corticosteroid therapy, regardless of immunization 
status. Also those that travel to areas where measles is 
endemic or contact with travellers to endemic areas, 
infants who lose passive antibody prior to the age of 
routine immunization, children with malnutrition, under-
lying immunodeficiency and vitamin A deficiency are at 
increased risk of contacting measles. 
 
Mortality Rate in Measles  
 
The mortality rate associated with uncomplicated mea-
sles in immunocompetent, well nourished children is 
low but is much higher in malnutrition (marked in Afri-
can children), in immunocompromised, and to lesser 
extent with age.  
 
Prominent features in Measles  
 
Modified Measles  
 
Modified measles occurs in children who have received 
serum immunoglobulin after their exposure to measles. 
The measles symptom complex may still occur, but the 
incubation period is as long as 21 days, with the same 




When exposed to the measles virus, a mild or nonexis-
tent prodrome of fever, headache, abdominal pain, and 
myalgias precedes a rash that begins on the hands and 
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feet and spreads centrally. The rash is most prominent i  
the body creases and may be macular, hemorrhagic 
vesicles, petechial, or urticarial. Complications may 
include pneumonia, pleural effusion, hilar lymphade-
nopathy, Hepatosplenomegaly, hyperesthesia, or pares-
thesia. Atypical measles occurs in individuals who were 
previously immunized with the killed measles vaccine 
between 1963 and 1967 and who have incomplete im-
munity.  
 
Subacute sclerosing panencephalitis (SSPE) 
 
It is a neurodegenerative disease caused by persistent 
infection of the brain by an altered form of the measl s 
virus. Neither the biology underlying the viral persis-
tence nor the triggering mechanism for viral reactivation 
is well understood. In most cases, infected children re-
main symptom-free for 6-15 years after acute measles 
infection. Subacute sclerosing panencephalitis (SSPE) is 
rare chronic, progressive encephalitis that affects pri-
marily children and young adults, caused by a persistent 
infection of immune resistant measles virus (which can 
be a result of a mutation of the virus itself). 1 in 100,000 
people infected with measles develop SSPE. SSPE is 
'incurable' but the condition can be managed by medica-
tion if treatment is started at an early stage.  
 
Clinical Presentation of SSPE  
 
Characterized by a history of primary measles infection 
usually before the age of 2 years, followed by several 
asymptomatic years (6–15 on average), and then grad-
ual, progressive psycho neurological deterioration, con-
sisting of personality change, seizures, myoclonus, 
ataxia, photosensitivity, ocular abnormalities, spasticity, 
and coma.  
 
Diagnosis of Measles  
 
Most cases of Measles are diagnosed clinically, usually 
in patient’s home or in General practice. Direct Vi-
rological confirmation is difficult in most of the devel-
oping countries.  
 
Diagnosis by Microscopy  
 
Production of multinucleate giant cells with inclusion 
bodies is path gnomonic for measles. During the prodro-
mal phase, such cells are detectable in the NPS 
(nasopharyngeal secretions). This is more rapid and
practical than virus isolation.  
                          
Diagnosis with Immunofluorescence 
 
 Direct and indirect immunofluorescence has been used 
extensively to demonstrate MV antigens in cells from 
NPS specimens. This technique can also be applied to 
the urine as such cells may be present in the urine 2 to 5 





Diagnosis by Viral Isolation  
 
Measles virus can be isolated from a variety of sources, 
e.g. throat or conjunctival washings, sputum, urinary 
sediment cells and lymphocytes. Primary human kidney 
(HEK) cells are the best, although primary monkey kid-
ney can be used as well. Continuous cell lines such as 
Vero cells can also be used although they are not as effi-
cient as primary cell lines. 
 
Diagnosis by Serology  
 
Diagnosis of measles infection can be made if the anti-
body titres rise by 4 fold between the acute and the con-
valescent phase or if measles-specific IgM is found. The 
methods that can be used include HAI, CF, neutraliza-
tion and ELISA tests.  
 
Differential diagnosis of measles  
 
1.   Rubella 
2.   Scarlet fever 
3.   Infectious mononucleosis, erythema infectiosum, 
echovirus and coxsackievirus infections  
4. Drug rashes (eg, from phenobarbital 
or sulfonamides 
 
How to distinguish measles from some other conditions  
 
• Rubella: A recognizable prodrome is absent, fever 
and other constitutional symptoms are absent or less 
severe, postauricular and suboccipital lymph nodes 
are enlarged (and usually tender), and duration is 
short. 
• Roseola infantum: The rash resembles that of mea-
sles, but it seldom occurs in children > 3 yr. Initial 
temperature is usually high, Koplik's spots and mal-
aise are absent, and defervescence and rash occur 
simultaneously. 
• Drug rashes: A drug rash often resembles the mea-
sles rash, but a prodrome is absent, there is no 
cephalocaudal progression or cough, and there is 




Some complications include; pneumonia, croup, pneu-
mothorax, bacterial superinfection, acute thrombocyt -
penic purpura, post-measles anergy, encephalitis, 





Severe complications from measles can be avoided 
though supportive care that ensures good nutrition, ade-
quate fluid intake and treatment of dehydration with 
WHO-recommended oral rehydration solution (to re-
place fluids and other essential elements lost from diar-
rhoea or vomiting). Antibiotics should be prescribed to 
treat eye and ear infections, and pneumonia.  
 
Treatment options in Developing Countries  
 
All children in developing countries diagnosed with 
measles should receive two doses of vitamin A  
supplements, given 24 hours apart. This can help pre-
vent eye damage and blindness. Vitamin A supplements 
have been shown to reduce the number of deaths from 




The Vaccines are live attenuated containing Edmonston 
B or Schwartz strains which will give seroconversion 
rate of 90%. The immunity produced may be lifelong. 
 
Changing trends for a Booster Dose  
 
In 2007, about 82% of the world's children received one 
dose of measles vaccine by their first birthday through 
routine health services, up from 72% in 2000. (Two 
doses of the vaccine are recommended to ensure immu-
nity, as it has been found that about 15% of vaccinated 
children fail to develop immunity from the first dose).  
 
Two doses of Measles Vaccine  
 
Continued progress depends on ensuring that all chil-
dren receive two doses of measles vaccine including one 
dose by their first birthday, strengthening disease sur-
veillance systems, and providing effective treatment for 
measles. However, in Nigeria, this two-dose vaccine 
policy has not yet been adopted. 
 
Global Initiatives  
 
The Measles Initiative - a collaborative effort of WHO, 
UNICEF, the American Red Cross, the United States 
Centres for Disease Control and Prevention, and the 
United Nations Foundation - and other public and pri-
vate partners play key roles in advancing the global 
measles strategy  
 
WHO and UNICEF are collaborating to ensure; 
 
• Strong routine immunization: for children by 
their first birthday.  
• A 'second opportunity' for measles immuniza-
tion through mass vaccination campaigns, to ensure 
that all children receive at least one dose.  
• Effective surveillance in all countries to quickly 
recognize and respond to measles outbreaks.  
• Better treatment of measles cases, to include  
        vitamin A supplements, antibiotics if needed, and  
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